Riskpilot← Back to searchSign inGet full accessCollabodoc AB
ABActiveOrg 5569126450Medborgarplatsen 25General medical practice activities · NACE 8621Est. 20121-4 employees
Revenue 2024
SEK 7,3M
-8% vs 2023
EBITDA margin
-27.3%
+22% vs 2023
Equity ratio
76.6%
Financial strength
Net profit 2024
SEK -2,4M
+18% vs 2023
| Revenue | SEK 7,3M | -8% |
| EBITDA | SEK -2M | +22% |
| Net profit | SEK -2,4M | +18% |
| Total assets | SEK 5,9M | -28% |
| Equity | SEK 4,5M | -34% |
| Employees | — | — |
Legal name
Collabodoc AB
Org number
5569126450
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
3 december 2012
Share capital
SEK 75 150
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva medicinsk och kirurgisk konsultverksamhet, utbildning och föreläsningar inom hälsa och ledarskap, utbildning och redaktionellt arbete inom naturvetenskap, medicinska webbtjänster samt därmed förenlig verksamhet.
Address
Medborgarplatsen 25
Email
staffan.bjessmo@collabodoc.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 9 367 | 9 266 | 8 659 | 6 515 | 9 351 | 7 926 | 7 272 |
| Staff expenses | — | — | — | — | — | — | — | — | −8 201 | −7 324 |
| EBITDA | 291 | 23 | 1 269 | 1 446 | 420 | 390 | −1 408 | −1 566 | −2 540 | −1 986 |
| Depreciation & amort. | −0 | −74 | −300 | −351 | −374 | −376 | −516 | −501 | −437 | −438 |
| EBIT | 291 | −51 | 969 | 1 095 | 46 | 14 | −1 924 | −2 067 | −2 978 | −2 423 |
| Net financials | 80 | −22 | 1 | 2 | 1 | −2 | 3 | 7 | 111 | 69 |
| Profit before tax | 273 | −34 | 970 | 1 096 | 106 | 11 | −1 921 | −2 059 | −2 866 | −2 354 |
| Tax | −65 | −0 | −222 | −248 | −30 | −3 | −0 | −0 | — | — |
| Net profit | 208 | −34 | 748 | 848 | 76 | 8 | −1 921 | −2 059 | −2 866 | −2 354 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 571 | 6 083 | 7 386 | 8 420 | 7 637 | 7 359 | 5 455 | 11 212 | 8 168 | 5 909 |
| Equity | 259 | 5 225 | 6 636 | 6 812 | 6 188 | 6 197 | 4 276 | 9 745 | 6 879 | 4 524 |
| Long-term debt | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | — | — |
| Short-term debt | 214 | 795 | 691 | 1 549 | 1 448 | 1 162 | 1 179 | 1 467 | 1 289 | 1 385 |
| Total debt | 214 | 798 | 691 | 1 549 | 1 448 | 1 162 | 1 179 | 1 467 | 1 289 | 1 385 |
EBITDA margin
-27.3%
This company
15.8%
Market median
-273% vs market
20152024
Equity ratio
76.6%
This company
38.2%
Market median
+101% vs market
20152024
Return on equity
-52.0%
This company
18.4%
Market median
-383% vs market
20152024
Net profit margin
-32.4%
This company
8.1%
Market median
-500% vs market
20152024
Asset turnover
1.23×
This company
1.12×
Market median
+10% vs market
20152024
Debt / equity
0.31×
This company
0.62×
Market median
+50% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LS Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
AM Audit | Audit | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Collabodoc AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Staffan Bjessmo | Chief Executive Officer | 0 companies |
| Anna Maria Wretholm | Audit | 0 companies |
| Rose-Marie Kropp | Board of Directors | 0 companies |
| Philip Walter Casimir Wrede | Board of Directors | 0 companies |
| Lena Hillevi Bjessmo | Deputy Board Member | 0 companies |
| Gisela Marie Sitbon | Board of Directors | 0 companies |
| Erik Olof Mikael Lönn | Board of Directors | 0 companies |
| Nils Hugo Eberhard Crona | Board of Directors | 0 companies |
| Eric Nils Gunnar Wahlberg | Chairman | 0 companies |